Personalized mRNA Vaccine Shows Potential in Melanoma Trial
Moderna and Merck reported on August 19, 2026, that a phase 3 trial of a personalized mRNA therapy for high-risk melanoma met two major treatment goals. The experimental vaccine, intismeran, was tested with Keytruda against Keytruda alone in patients whose stage IIB-IV melanoma had been surgically removed.
The combination improved recurrence-free survival, measuring the time before cancer returns or death occurs, and distant metastasis-free survival, measuring the time before cancer spreads elsewhere or death. However, the companies have not released detailed phase 3 efficacy or safety data, limiting independent assessment of the findings. They plan to present full results at a medical meeting and submit them to regulators.
Intismeran is manufactured individually using genetic information from each patient’s tumor. The therapy encodes up to 34 neoantigens, proteins created by tumor mutations, to train T cells to recognize and attack cancer cells. Keytruda, a PD-1 checkpoint inhibitor, supports immune activity by blocking signals that restrain the body’s response to cancer.
Earlier phase 2b data found that the combination was associated with a 49% lower risk of recurrence or death and a 59% lower risk of distant metastasis or death compared with Keytruda alone. Those results, while supportive, do not substitute for the full phase 3 analysis.
Outside experts described the announcement as encouraging but said several questions remain. Researchers need to determine the size and durability of any added benefit and whether the personalized vaccine increases immune-related side effects, including inflammation or autoimmune complications.
The trial remains ongoing, and intismeran is investigational and not approved by the Food and Drug Administration. The findings indicate that personalized mRNA vaccines may eventually complement established melanoma immunotherapy. Their clinical role, however, will depend on peer-reviewed results, regulatory review, and clearer evidence about effectiveness, safety, patient selection, manufacturing demands, access, cost, and long-term outcomes overall.